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Reframing the varenicline question: have anecdotes and 
emotional ﬁ lters clouded our decision making?
In searching for an appropriate way to begin describing 
our impressions of the retrospective cohort analysis 
by Daniel Kotz and colleagues,1 published in The Lancet 
Respiratory Medicine, we were tempted to rely on worn 
but reliable observations regarding the magnitude of the 
tobacco epidemic. Smoking is the single most common 
cause of preventable death and disability, as the refrain 
goes. After reading Kotz and colleagues’ report1 on the 
cardiovascular and neuropsychiatric risks of varenicline, 
however, something about that oft-quoted phrase 
became quite a bit more discomﬁ ting. Could a portion of 
the epidemic’s persistence, we wondered, be attributable 
to the way clinicians, scientists, and individual smokers 
think about risk? What portion of preventable death and 
disability have we simply failed to prevent? 
Shortly after varenicline was introduced to American 
and European markets for the treatment of tobacco 
dependence, concerns regarding its potential adverse 
eﬀ ects began to take form. Earliest post-marketing 
surveillance reports suggested that users were reporting 
various dangerous psychiatric side-eﬀ ects, including 
hallucinations, memory loss, rage, depression, and 
suicidal behaviours. Soon thereafter, treatment with 
varenicline was used as a plausible defense in trials 
involving violent crimes. The European Medicines Agency 
(EMA) ﬁ rst alerted the US Food and Drug Administration 
(FDA) to concerns over varenicline’s association with 
suicidality in May, 2007. Government regulators on both 
sides of the Atlantic adopted a justiﬁ ably protective 
stance, urging patients and clinicians to proceed 
cautiously with their treatment decisions.2,3
Several investigators went to work reporting results 
of sophisticated observational analyses, involving 
progressively larger cohorts of patients with sample 
sizes reaching the tens of thousands, with results 
suggesting that the initial concern might have been 
unwarranted.4,5 Yet natural human preference for 
avoiding risk led to regulatory inaction and the 
persistence of anecdotal contraindications to treatment 
within the clinical community. Even prospective trials 
of the safety and eﬃ  cacy of varenicline in patients 
with pre-existing serious mental illness seemed to be 
insuﬃ  cient to overcome a powerful omission bias.6–8 
So far, the available evidence does not seem to have 
yet risen to the level of certainty necessary to shake the 
fear adopted as a result of the initial anecdotal post-
marketing surveillance reports.
During the same period, in a remarkable example 
of surveillance déjà vu, reports of a connection 
between varenicline use and an increased risk for 
cardiovascular adverse events emerged. Although 
the numbers of events were small, and cardiovascular 
outcomes reported did not necessarily have a common 
pathophysiological mechanism, nagging concerns once 
again resulted in a regulatory position that reﬂ ected 
a better-safe-than-sorry stance, despite good data 
suggesting that the initial associations might have 
been overblown.9 Again, comfort was found in the false 
security of waiting for more data.
Hopefully, Kotz and colleagues’ report1 will help to 
clarify the signals that have been emerging for several 
years now. In a real-world practice setting across 
England, they compared validated follow-up data from 
more than 51 000 users of varenicline with data from 
nearly 107 000 patients prescribed nicotine and more 
than 6500 patients prescribed bupropion. Hazard ratios 
(HRs) for conditions of concern were raised in neither the 
propensity-matched varenicline group nor bupropion 
groups. In fact, varenicline seemed to have a protective 
eﬀ ect for many of the adverse events analysed (eg, self-
harm [HR 0·56, 95% CI 0·46–0·68], heart failure [0·61, 
0·45–0·83], and cerebral infarction [0·62, 0·52–0·73]), 
perhaps as a function of its unique pharmacological 
eﬀ ect. In a nice example of epidemiological precision, 
Kotz and colleagues calculated the eﬀ ect that an 
uncaptured confounder would need to have to negate 
the primary analysis result. The observed eﬀ ect was so 
persistent that an unanticipated confounder would have 
to have both a very strong eﬀ ect and an extremely biased 
distribution within the sample, making the likelihood 
that such a confounder might actually exist virtually nil.
The investigators did miss an important opportunity 
to present a complete picture by omitting comparator 
groups of non-smokers and untreated smokers. 
Although the incidence of events did not seem to be 
adversely related to treatment with varenicline, the 
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observed event rates for depression and ischaemic heart 
disease seemed to be higher than expected in a general 
population.10 Reframing these observations, however, 
conﬁ rms what clinicians have known for decades: 
nicotine addiction represents a profound disturbance 
in brain biology, manifesting as a compulsive disorder 
with a wide array of predictable consequences. In 
other words, ischaemic events, depression, and other 
neuropsychiatric eﬀ ects might be a function of tobacco 
dependence and recovery, rather than an eﬀ ect of the 
drug choices made during treatment.
Treating tobacco dependence involves a series of 
personal and professional calculations, sometimes 
messy and coloured by intense emotions. Against this 
backdrop, the implications of Kotz and colleagues’ study 
go beyond its obvious points regarding varenicline side-
eﬀ ects. To understand the true relevance of this work 
requires placing it within historical context, and asking 
some diﬃ  cult questions about our own risk-aversive 
nature. For the past decade, clinicians have been faced 
with opposing signals from the ﬁ eld. Are adverse events 
a function of the treatment or the disease? Exactly 
how safe does a safe medication need to be when 
weighed against the burden of illness caused by tobacco 
dependence? Should reliance on anecdotal case reports 
be allowed when making treatment decisions? How big 
do observational studies need to be before the guidance 
they provide can be trusted? Would the answers to these 
questions be diﬀ erent if the questions weren’t about 
smoking? By providing precise risk estimates associated 
with the treatment options, Kotz and colleagues’ study 
should allow us to move on comfortably, and begin to 
examine the nature of our internal calculus of risk with 
respect to what remains as the single greatest cause of 
premature death and disability around the world.
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 Elucidating COPD pathogenesis by large-scale genetic analyses
Chronic obstructive pulmonary disease (COPD) is a 
heterogeneous syndrome deﬁ ned by the presence of 
chronic airﬂ ow limitation and associated with other 
clinical and pathological hallmarks, such as chronic 
bronchitis, emphysema, exacerbations, and comorbidities. 
COPD is a complex disease, suggesting that both genetic 
susceptibility and environmental exposures (eg, cigarette 
smoking and smoke from biomass fuels) contribute to its 
pathogenesis (ﬁ gure). In The Lancet Respiratory Medicine, 
Louise Wain and colleagues1 report intriguing novel 
insights into the genetics of smoking behaviour and the 
airﬂ ow obstruction component of COPD.
The genetic study done by the UK Biobank Lung Exome 
Variant Evaluation (UK BiLEVE) collaborators has many 
assets.1 First, big is beautiful in genetics. More than 
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